Skip to main content
. 2015 Oct 8;17:279. doi: 10.1186/s13075-015-0795-y

Fig. 1.

Fig. 1

Change in flow-mediated vasodilation (FMD) from baseline to study end. Change in flow-mediated vasodilation (FMD) (%) from baseline to study end in patients with inflammatory joint diseases and established atherosclerosis (n = 85) after 18 months of rosuvastatin treatment. FMD flow-mediated vasodilation, SE standard error, SD standard deviation